The Targeted Pro & Prebiotic for Kidney Health Supplement, Renadyl™, an AAKP HealthLine Innovator webinar sponsored by Kibow Biotech, Inc.

You will learn about Renadyl™, a targeted Pro and Prebiotic supplement developed by Kibow Biotech, Inc., which supports kidney health when used in conjunction with the standard of care for CKD patients. You will also learn about the science behind this strainspecific technology platform, built on targeted pro and prebiotics. A brief overview of Kibow Biotech will give you a quick glimpse into the company's 25 years of R&D.

In addition, you will hear about Kibow’s ongoing clinical trials with KT301, a promising new investigational "drug," the first pro & prebiotic to receive an Investigational New Drug (IND) Application from the U.S. Food & Drug Administration to conduct clinical trials.

The content of this program, as presented, and financial support of this webinar was provided by Kibow Biotech, Inc.

As the oldest and largest patientled kidney patient organization in the U.S., AAKP is proud to host this Innovator webinar as a service to the expanding national and global communities of patient consumers and their families, medical practitioners, researchers, and policymakers following innovation and advancements in kidney care and treatment.

AAKP is an aggressive supporter of innovation to change status quo care.

While this activity is an approved educational webinar, AAKP does not endorse this webinar nor endorse or promote any specific commercial entities or products.

About AAKP: AAKP is dedicated to improving the lives and longterm outcomes of kidney patients through education, advocacy, patient engagement and the fostering of patient communities. AAKP fights for early disease detection and the appropriate diagnosis of rare/genetic conditions; increased kidney transplantation and preemptive transplantation; full patient choice of either incenter or home dialysis; protection of the patient/physician relationship; promotion of research and innovation including artificial implantable and wearable kidneys and xenotransplantation; and the elimination of barriers for patient access to available treatment options. Visit us at www.aakp.org and follow us on social media at Facebook @kidneypatient and Twitter/Instagram @kidneypatients.